Fluticasone furoate nasal spray (Lek Pharmaceuticals)

Phase 3

Sandoz Group AG (SDZ.SW)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Rhinitis, Allergic, Seasonal

ALPMYASP4070

Phase 2

DVAXAmb a 1 Immunostimulatory Oligoribonucleotide Conjugate

Phase 2

View Full Landscape

Drug Information

Target Indication

Rhinitis, Allergic, Seasonal

Clinical Trial

NCT01279057

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA10/6/2008

Alisade

Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.

View on EMA

EMA1/11/2008

Avamys

Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SDZ.SW

Sandoz Group AG

Pharmaceutical Preparations•Europe•SIX

Related Pipeline

HX575, solution for injection (s.c.)Phase 3

Anemia

GP2015 EtanerceptPhase 3

Chronic Stable Plaque Psoriasis

GP2013Phase 3

Follicular Lymphoma

HX575 epoetin alfaPhase 3

Anemia

HX575 epoetin alfa (Sandoz)Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts